Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL

NCT06742502 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Primary Mediastinal Diffuse Large B-cell Lymphoma

Interventions

DRUG: Sintlimab+Rituximab follwed by R-CHOP(Cyclophosphamide, doxorubicin, vincristine, prednisone)

Sponsor

Sun Yat-sen University